<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459794</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00005069</org_study_id>
    <nct_id>NCT03459794</nct_id>
  </id_info>
  <brief_title>Ivermectin and Human Immunity</brief_title>
  <official_title>The Effects of Ivermectin on Human Innate Immunity Against Filarial Parasites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Georgia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts
      with the human innate immune system and that this contributes to its anti-parasitic effects.
      Participants will donate blood before and after being administered the normal human dose of
      the drug. We will compare the cell types present in the blood and the chemicals known to
      influence the human immune system before and after the drug is given, as well as measuring
      any changes in gene expression in white blood cells 4 and 24hrs after the drug is taken.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will visit the University of Georgia (UGA) Clinical &amp; Translation Research Unit
      (CTRU) twice on consecutive days and blood will be drawn from them. On the first occasion
      they will be weighed and will complete the consent process. They will have been randomly
      assigned to the test (Stromectol) or control (placebo) group, with 8 participants in the test
      group and 4 participants in the control group. Stromectol will be obtained from a medical
      supply distributor and a placebo will be obtained through the UGA School of Pharmacy. Drugs
      will be prescribed by Jonathan Murrow MD. They will be stored in their original packaging at
      room temperature in a drug locker in the lab at CTRU. Participants will be identified by
      number and allocated to groups using a block randomization protocol. Randomization and drug
      dispensation will be done by CTRU. Eighteen ml of blood will drawn in a fasting state and
      they will be administered 150 mcg/kg Stromectol or the equivalent number of placebo tablets
      immediately after blood is drawn. Participants will remain at CTRU for four hours after they
      take the drug, then another 15ml of blood will be drawn. On the second day they will attend
      CTRU at the same time and the third blood sample will be drawn 24 hrs after administration of
      the drug. On each occasion the drawn blood will be coded by CTRU staff prior to being
      collected by a member of the Department of Infectious Diseases and taken to the laboratory
      (Wildlife Health G0007) for the isolation of leukocyte populations (peripheral monocytes,
      lymphocytes and polymorphonuclear cells (PMNs)) and for the preparation of serum. Complete
      blood counts will also be carried out. Sera will be analyzed on the Luminex for
      cytokine/chemokine content. RNA will be isolated from the cell populations for RNASeq
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 9, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded.</measure>
    <time_frame>Pre-treatment, 4 hours and 24 hours post-treatment</time_frame>
    <description>Changes in serum levels of a panel of 41 cytokines will be compared to baseline levels using Luminex methods (HCYTOMAG-60K-PX41 kit from EMD Millipore). No pre-specified threshold was set for biological significance, and the number of cytokines showing a statistically significant (p=&lt;0.05) change from time 0 for each group will be reported. The number of cytokines with significant changes is taken from a comparison of the mean levels in each of the groups, not at the level of individual participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Transcripts in PBMC With Statistically Significant Changes From Pre-treatment Levels.</measure>
    <time_frame>Pre-treatment, 4 hours and 24 hours post-treatment</time_frame>
    <description>Changes in expression levels of approximately 770 genes involved in innate immunity will be measured in peripheral blood mononuclear cells (PBMC) before and after treatment. The number of transcripts with significant changes is taken from a comparison of the mean levels in each of the groups, not at the individual participant level. No pre-determined threshold was set for the biological significance of these changes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Blood Counts (CBC)</measure>
    <time_frame>Pre-treatment (0hrs), 24 hours</time_frame>
    <description>CBCs will be performed before treatment and 24 hrs later</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Ivermectin</condition>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin will be administered once at 150mcg/kg, orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An oral placebo will be administered once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>150 mcg/kg ivermectin, by mouth.</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An oral placebo will be administered, once</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight over 110 pounds and under 185 pounds

        Exclusion Criteria:

          -  Pregnancy or nursing mothers.

          -  Immunosuppressed individuals.

          -  Hypersensitivity to ivermectin, cellulose, starch, magnesium stearate, butylated
             hydroxyanisole, or citric acid powder (inert ingredients of Stromectol).

          -  Recent (last 3 years) travel to West or Central Africa, or any other country where
             onchocerciasis is present

          -  Hepatitis/HIV

          -  Currently taking warfarin

          -  Lactose intolerance (Lactose present in placebo)

          -  Currently taking Steroid medications (inhaled, oral or injection)

          -  Currently taking Barbiturates, Benzodiazepines such as Xanax or Klonopin, Valproic
             acid (Lithium), Calcium channel blockers, Statins (cholesterol medication)

          -  Liver or renal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian J Wolstenholme, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Georgia</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <results_first_submitted>January 10, 2019</results_first_submitted>
  <results_first_submitted_qc>April 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2019</results_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Georgia</investigator_affiliation>
    <investigator_full_name>Adrian Wolstenholme</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03459794/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ivermectin</title>
          <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ivermectin</title>
          <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded.</title>
        <description>Changes in serum levels of a panel of 41 cytokines will be compared to baseline levels using Luminex methods (HCYTOMAG-60K-PX41 kit from EMD Millipore). No pre-specified threshold was set for biological significance, and the number of cytokines showing a statistically significant (p=&lt;0.05) change from time 0 for each group will be reported. The number of cytokines with significant changes is taken from a comparison of the mean levels in each of the groups, not at the level of individual participants.</description>
        <time_frame>Pre-treatment, 4 hours and 24 hours post-treatment</time_frame>
        <population>Cytokines were measured in sera using the HCYTOMAG-60K-PX41 kit from EMD Millipore. The numbers reported are the number of cytokines with statistically significant changes ( p = &lt;0.05) from pre-treatment levels.</population>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin 4hrs</title>
            <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth. 4 hrs post-treatment</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin 24 Hrs</title>
            <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth.24 hrs post-treatment</description>
          </group>
          <group group_id="O3">
            <title>Control 4 Hrs</title>
            <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once. Sera collected 4hrs post-treatment</description>
          </group>
          <group group_id="O4">
            <title>Control 24 Hrs</title>
            <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once. Sera collected 24hrs post-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded.</title>
          <description>Changes in serum levels of a panel of 41 cytokines will be compared to baseline levels using Luminex methods (HCYTOMAG-60K-PX41 kit from EMD Millipore). No pre-specified threshold was set for biological significance, and the number of cytokines showing a statistically significant (p=&lt;0.05) change from time 0 for each group will be reported. The number of cytokines with significant changes is taken from a comparison of the mean levels in each of the groups, not at the level of individual participants.</description>
          <population>Cytokines were measured in sera using the HCYTOMAG-60K-PX41 kit from EMD Millipore. The numbers reported are the number of cytokines with statistically significant changes ( p = &lt;0.05) from pre-treatment levels.</population>
          <units>Cytokines changed from t=0</units>
          <param>Number</param>
          <units_analyzed>Cytokines</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Cytokines</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All measurements were compared to the same group at t=0, that is before the drug or placebo was administered. We compared the expression levels for each transcript, using the mean levels in each group, not at the individual participant level.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>We analyzed the changes is level for each cytokine between the groups. P value was adjusted for multiple comparisons and significance determined using the Holm-Sidak method. The threshold value for statistical significance for the mean value between groups was set at p =&lt;0.05 for each cytokine measured. The number of cytokines that met this threshold is reported.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Transcripts in PBMC With Statistically Significant Changes From Pre-treatment Levels.</title>
        <description>Changes in expression levels of approximately 770 genes involved in innate immunity will be measured in peripheral blood mononuclear cells (PBMC) before and after treatment. The number of transcripts with significant changes is taken from a comparison of the mean levels in each of the groups, not at the individual participant level. No pre-determined threshold was set for the biological significance of these changes.</description>
        <time_frame>Pre-treatment, 4 hours and 24 hours post-treatment</time_frame>
        <population>Levels of 770 messenger RNAs (mRNAs) were assayed in PBMC isolated from study participants using the Human Nanostring Myeloid cell panel.</population>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin 4hrs</title>
            <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth. 4 hrs post-treatment</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin 24 Hrs</title>
            <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth.24 hrs post-treatment</description>
          </group>
          <group group_id="O3">
            <title>Control 4 Hrs</title>
            <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once. Sera collected 4hrs post-treatment</description>
          </group>
          <group group_id="O4">
            <title>Control 24 Hrs</title>
            <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once. Sera collected 24hrs post-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Transcripts in PBMC With Statistically Significant Changes From Pre-treatment Levels.</title>
          <description>Changes in expression levels of approximately 770 genes involved in innate immunity will be measured in peripheral blood mononuclear cells (PBMC) before and after treatment. The number of transcripts with significant changes is taken from a comparison of the mean levels in each of the groups, not at the individual participant level. No pre-determined threshold was set for the biological significance of these changes.</description>
          <population>Levels of 770 messenger RNAs (mRNAs) were assayed in PBMC isolated from study participants using the Human Nanostring Myeloid cell panel.</population>
          <units>Transcripts signicantly changed from t=0</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All measurements were compared to the same treated/control group at t=0, before the drug or placebo was administered. We compared the expression levels for each transcript, using the mean levels in each group, not at the individual participant level.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>We compared the expression levels for each transcript, using the mean levels in each group, not at the individual participant level. The p-value for each transcript is adjusted for multiple comparisons across all 770 transcripts, using the Benjamini-Yekutieli method. The number reported is the number of transcripts where p=&lt;0.05.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Blood Counts (CBC)</title>
        <description>CBCs will be performed before treatment and 24 hrs later</description>
        <time_frame>Pre-treatment (0hrs), 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ivermectin 0 Hrs</title>
            <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth. Blood collected at t=0</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin 24 Hrs</title>
            <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth.Blood collected 24 hrs post-treatment</description>
          </group>
          <group group_id="O3">
            <title>Control 0 Hrs</title>
            <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once. Blood collected at t=0</description>
          </group>
          <group group_id="O4">
            <title>Control 24 Hrs</title>
            <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once. Blood collected 24hrs post-treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Blood Counts (CBC)</title>
          <description>CBCs will be performed before treatment and 24 hrs later</description>
          <units>Million cells/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.069" spread="0.353"/>
                    <measurement group_id="O2" value="3.341" spread="0.426"/>
                    <measurement group_id="O3" value="2.940" spread="0.18"/>
                    <measurement group_id="O4" value="3.358" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.753" spread="0.22"/>
                    <measurement group_id="O2" value="1.864" spread="0.151"/>
                    <measurement group_id="O3" value="1.833" spread="0.161"/>
                    <measurement group_id="O4" value="2.075" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.483" spread="0.045"/>
                    <measurement group_id="O2" value="0.403" spread="0.057"/>
                    <measurement group_id="O3" value="0.373" spread="0.04"/>
                    <measurement group_id="O4" value="0.375" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.208" spread="0.055"/>
                    <measurement group_id="O2" value="0.205" spread="0.047"/>
                    <measurement group_id="O3" value="0.158" spread="0.015"/>
                    <measurement group_id="O4" value="0.170" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.008"/>
                    <measurement group_id="O2" value="0.046" spread="0.006"/>
                    <measurement group_id="O3" value="0.048" spread="0.008"/>
                    <measurement group_id="O4" value="0.048" spread="0.0005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day following administration of the drug/placebo</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ivermectin</title>
          <description>Ivermectin will be administered once at 150mcg/kg, orally.
Ivermectin: 150 mcg/kg ivermectin, by mouth.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>An oral placebo will be administered once
Placebo: An oral placebo will be administered, once</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Minor gastrointestinal upset</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Adrian Wolstenholme</name_or_title>
      <organization>University of Georgia</organization>
      <phone>706 542 2404</phone>
      <email>adrianw@uga.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

